Julien Miara, Chairperson and CEO of Valerio Therapeutics, commented, “This decision, which will help consolidate the financial position of the company together with other actions, allows us to focus on our core strengths in early-stage research while preserving financial flexibility to drive transformative innovation. We extend our gratitude to the patients, investigators, and partners who have supported our clinical efforts and remain steadfast in our mission to develop novel therapies addressing critical unmet needs.”
Valerio is committed to providing updates on its revised strategy and future plans in due course.
